Menade du:
"so opens" » "o opens" (Utvidga sökningen), "so open" (Utvidga sökningen), "who opens" (Utvidga sökningen), "sao opens" (Utvidga sökningen), "so openss" (Utvidga sökningen), "sso opens" (Utvidga sökningen)
"eso open" » "so open" (Utvidga sökningen), "caso open" (Utvidga sökningen), "two open" (Utvidga sökningen), "esao open" (Utvidga sökningen), "eso opens" (Utvidga sökningen), "esso open" (Utvidga sökningen)
"do open" » "two open" (Utvidga sökningen), "oto open" (Utvidga sökningen), "dao open" (Utvidga sökningen), "do opens" (Utvidga sökningen), "dso open" (Utvidga sökningen)
"o open" » "ao open" (Utvidga sökningen), "o opens" (Utvidga sökningen), "so open" (Utvidga sökningen)
"esmo open" » "esmao open" (Utvidga sökningen), "esmo opens" (Utvidga sökningen), "esmso open" (Utvidga sökningen), "esto open" (Utvidga sökningen), "ecmo open" (Utvidga sökningen)
Visas 1 - 20 av 1 029 resultat för sökning '(((((("eso open") OR ("o open"))) OR ("esmo open"))) OR ((("do open") OR ("so opens"))))', Sökningstid : 2,97s Förfina resultatet
AIOM chooses ESMO Open—Cancer Horizons as its official journal: a warm welcome from ESMO Open
ESMO Open—Cancer Horizons and the future of oncology

CSCO joins ESMO Open—Cancer Horizons
ESMO Open: news in breast cancer 2019

ESMO Open welcomes the association with the Japanese Society of Medical Oncology (JSMO)
ESMO Open special series on new emerging targets in cancer immunotherapy

Announcing the ESMO Open special issue on upcoming molecular targets for cancer treatment
One year of ESMO Open: Cancer Horizons—where are we going from here?

Plasmodesmata. A Not So Open-and-Shut Case
Introducing a new ESMO Open article series: how I treat side effects of immunotherapy

Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open–Cancer Horizons roundtable discussion
First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion

CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open—Cancer Horizons pro and con discussion
Desafios do Open Design

New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an “ESMO Open – Cancer Horizons” Series
Erratum to ‘FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?’: [ESMO Open Volume 5, Issue 5, 2020, e000633]

Adoção do Open Peer Review
How do Openers Contribute to Student Learning?

Criptografia digital: implementação do OpenPGP
Erratum to ‘Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis’: [ESMO Open Volume 6, Issue 2, April 2021, 100088]

Sökverktyg: RSS-flöde — Skicka sökningen per e-post — Spara sökningen